
A clinical trial comparing erenumab and nonspecific oral migraine preventive medications (OMPMs) for patients with episodic migraine (EM) who had previously failed 1 or 2 preventive treatments found significant differences in efficacy, tolerability, and patient adherence. Of the 621 randomized patients, those receiving erenumab showed significantly higher rates of achieving the primary endpoint (56.2% vs 16.8%) and responder rates (76.0% vs 18.8%) at month 12. Erenumab also led to a significant reduction in migraine days and fewer patients switching medication or discontinuing due to adverse events compared to OMPMs. The study concludes that erenumab offers greater and sustained efficacy, safety, and adherence in these patients.
Like
Save
Share